Research Papers:
Regulatory B cells induced by pancreatic cancer cellderived interleukin18 promote immune tolerance via the PD1/PDL1 pathway
PDF | Full Text | How to cite
Yan Zhao1, Ming Shen1, Yecheng Feng1, Ruizhi He1, Xiaodong Xu1, Yu Xie1, Xiuhui Shi1, Min Zhou1, Shutao Pan1, Min Wang1, Xingjun Guo1 and Renyi Qin1
1Department of Biliary-Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Correspondence to:
Xingjun Guo, email: xjguo@tjh.tjmu.edu.cn
Renyi Qin, email: ryqin@tjh.tjmu.edu.cn
Keywords: pancreatic cancer; interleukin-18; regulatory B cells; immune tolerance; PD-1/PD-L1 pathway
Received: May 19, 2017 Accepted: November 14, 2017 Epub: December 07, 2017 Published: March 13, 2018
ABSTRACT
Dysregulation of regulatory B cells (Bregs), a type of immunosuppressive lymphocyte, are associated with development of autoimmune diseases and cancers. Bregs produce immune tolerance-inducing cell surface molecules and tolerogenic cytokines (interleukin [IL]-10 and transforming growth factor-beta). We previously showed that levels of the inflammatory cytokine IL-18 were increased in patients with pancreatic cancer. In the present study study, we found that pancreatic cancer cell-derived IL-18 increases Breg-induced immunosuppression. IL-18 also promoted B-cell proliferation and IL-10 expression in vivo and in vitro. In addition, IL-18 upregulated membrane PD-1 in B cells and inhibited the antibody-dependent cellular cytotoxicity of Tc cells and natural killer cells. Finally, the combination of a natural IL-18 inhibitor (IL-18BP) and a PD-1/PD-L1 inhibitor suppressed tumor growth and metastasis in a murine pancreatic cancer model. Our results show that IL-18 and PD-1/PD-L1 could be therapeutic targets in pancreatic cancer.